MedTrace Logo

Hyperuricemia on Hypertension and Metabolic Syndrome

NCT01157936 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-07-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the influence of hyperuricemia treatment compared with placebo on participants with high risk of hypertension and metabolic syndrome.

Conditions

  • Systolic and Diastolic Blood Pressure Levels
  • Uric Acid Levels
  • Metabolic Syndrome Parameters
  • Hepatic Enzymes

Interventions

DRUG

Allopurinol

daily dosage

OTHER

placebo

daily dosage

Sponsors & Collaborators

  • National Council of Science and Technology, Mexico

    collaborator OTHER

  • Instituto Nacional de Cardiologia Ignacio Chavez

    lead OTHER

Principal Investigators

  • Magdalena Madero, MD · Instituto Nacional de Cardiología Ignacio Chávez

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-02-28
Completion
2011-08-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01157936 on ClinicalTrials.gov